In addition, in subtypes with mTOR overexpression or PTEN loss with alteration in the Rb-CDK4/6 pathway as a secondary driver such as leiomyosarcoma, angiosarcoma and osteosarcoma, combination therapies with CDK inhibitors and mTOR or PI3K inhibitors might be a potential therapeutic option. This evidence concerns the gene MTOR and leiomyosarcoma.